Table 1.
Demographic, Baseline and Treatment Characteristics
| Total N = 270 (%) | Early Bone Metastases (eBM) N = 72 (%) | No Early Bone Metastases (nBM) N = 198 (%) | P-Value | |
| Sex | ||||
| Male | 181 (67) | 52 (72) | 129 (65) | 0.274 |
| Female | 89 (33) | 20 (28) | 69 (35) | |
| Mean Age±SD | 66.8±10.7 | 68.0±11.0 | 69.1±10.7 | 0.432 |
| Smoking History | 193 (72) | 54 (76) | 139 (71) | 0.407 |
| Primary Site | ||||
| Bladder | 211 (78) | 60 (83) | 151 (76) | 0.214 |
| Upper Tract | 59 (22) | 12 (17) | 47 (24) | |
| Histology | ||||
| Urothelial | 214 (80) | 65 (90) | 149 (76) | 0.008 |
| Mixed / Variant | 55 (20) | 7 (10) | 48 (24) | |
| NAC∗ | 69 (34) | 14 (33) | 55 (34) | 0.920 |
| Cisplatin | 63 (90) | 12 (80) | 51 (93) | 0.302 |
| Carboplatin | 6 (9) | 3 (20) | 3 (6) | |
| Adjuvant Chemotherapy | 28 (11) | 3 (4) | 25 (13) | 0.040 |
| Definitive Surgery | 147 (54) | 28 (39) | 119 (60) | 0.002 |
| Median TTM (range)† | 10.6 (1.1 –91.3) | 17.0 (1.1 –76.3) | 10.0 (1.5 –91.3) | 0.459 |
| De-novo metastatic | 67 (25) | 30 (42) | 37 (19) | <0.001 |
| Metastatic Sites‡ | ||||
| Lymph Node | 154 (57) | 35 (49) | 119 (60) | 0.092 |
| Lung | 95 (35) | 23 (32) | 72 (36) | 0.501 |
| Liver | 59 (22) | 19 (26) | 40 (20) | 0.277 |
| Lymph Node Only | 81(30) | 16(22) | 65(33) | 0.093 |
| ECOG PS§ | 0.057 | |||
| 0 | 63 (28) | 13 (21) | 50 (31) | |
| 1 | 102 (46) | 27 (44) | 75 (46) | |
| ≥2 | 58 (26) | 21 (34) | 37 (23) | |
| Initial Treatment | 0.041 | |||
| Platinum-based | 139 (52) | 45 (63) | 94 (48) | |
| Immune Checkpoint Inhibitor | 92 (34) | 16 (22) | 76 (38) | |
| Other | 39 (14) | 11 (15) | 28 (14) | |
| Initial Treatment: Platinum | 0.532 | |||
| Cisplatin | 75 (54) | 26 (58) | 49 (52) | |
| Carboplatin | 64 (46) | 19 (42) | 45 (48) | |
| Initial Treatment: ICI | 0.296 | |||
| Pembrolizumab | 50 (54) | 11 (69) | 39 (51) | |
| Atezolizumab | 35 (38) | 5 (31) | 30 (40) | |
| Nivolumab | 7 (8) | 0 | 7 (9) |
∗NAC=Neoadjuvant Chemotherapy; †TTM = Time from definitive surgery to metastases development in months; ‡Metastatic disease may have been identified in more than one site with exception of lymph node only; §ECOG Performance Status at start of initial treatment, missing 17% of data